HER2-Negative Metastatic Breast Cancer – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

HER2-Negative Metastatic Breast Cancer Market Outlook

Thelansis’s “HER2-Negative Metastatic Breast Cancer Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential HER2-Negative Metastatic Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

HER2-Negative Metastatic Breast Cancer Overview

Breast cancer stands as the most prevalent affliction among women globally, exerting a significant toll on mortality rates. HER2-negative breast cancer encompasses various subtypes, including normal-like breast cancer, luminal A, partial luminal B, and basal-like varieties. Potential inhibitors for treating HER2-negative breast cancer include PI3K inhibitors, AKT inhibitors, and mTOR inhibitors, which effectively suppress the PI3K/AKT signaling pathway. Additionally, small molecule tyrosine kinase inhibitors hinder angiogenesis, while CDK inhibitors, aurora kinase inhibitors, and HDAC inhibitors disrupt the cell cycle. Moreover, drugs targeting breast cancer stem cells have garnered attention, offering innovative strategies for combating HER2-negative breast cancer. The PI3K pathway can be roughly categorized into type I, II, and III, with type I further divided into IA and IB. At the heart of the PI3K/AKT pathway, AKT is regulated by diverse upstream signaling proteins, orchestrating gene transcription, protein synthesis, and cell survival and proliferation through various downstream pathways. Furthermore, mTOR, a pivotal kinase downstream of the PI3K/AKT pathway, comprises mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). Mesenchymal stem cells (MSCs) have emerged as promising therapeutic agents for targeting breast cancer stem cells (BCSCs) in cell-targeted breast cancer therapy. Additionally, long non-coding RNA (lncRNA) and microRNA (miRNA) demonstrate the ability to regulate CSC proliferation, offering significant potential in treating HER2-negative breast cancer.

• The age-adjusted rate of HER2-negative breast cancer is 13.2 cases per 100,000 women in the USA.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: